Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Rong-Hui Du, Li-Rong Liang, Cheng-Qing Yang, Wen Wang, Tan-Ze Cao, Ming Li, Guang-Yun Guo, Juan Du, Chun-Lan Zheng, Qi Zhu, Ming Hu, Xu-Yan Li, Peng Peng, Huan-Zhong Shi, Rong-Hui Du, Li-Rong Liang, Cheng-Qing Yang, Wen Wang, Tan-Ze Cao, Ming Li, Guang-Yun Guo, Juan Du, Chun-Lan Zheng, Qi Zhu, Ming Hu, Xu-Yan Li, Peng Peng, Huan-Zhong Shi

Abstract

The aim of this study was to identify factors associated with the death of patients with COVID-19 pneumonia caused by the novel coronavirus SARS-CoV-2.All clinical and laboratory parameters were collected prospectively from a cohort of patients with COVID-19 pneumonia who were hospitalised to Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between 25 December 2019 and 7 February 2020. Univariate and multivariate logistic regression analysis revealed that age ≥65 years (OR 3.765, 95% CI 1.146–17.394; p=0.023), pre-existing concurrent cardiovascular or cerebrovascular diseases (OR 2.464, 95% CI 0.755–8.044; p=0.007), CD3+CD8+ T-cells ≤75 cells·μL−1 (OR 3.982, 95% CI 1.132–14.006; p<0.001) and cardiac troponin I ≥0.05 ng·mL−1 (OR 4.077, 95% CI 1.166–14.253; p<0.001) were associated with an increase in risk of mortality from COVID-19 pneumonia.” has been corrected to: “Univariate and multivariate logistic regression analysis revealed that age ≥65 years (OR 3.765, 95% CI 1.201−11.803; p=0.023), pre-existing concurrent cardiovascular or cerebrovascular diseases (OR 2.464, 95% CI 1.279−4.747; p=0.007), CD3+CD8+ T-cells ≤75 cells·μL−1 (OR 3.982, 95% CI 1.761–9.004; p<0.001) and cardiac troponin I ≥0.05 ng·mL−1 (OR 4.077, 95% CI 1.778–9.349; p<0.001) were associated with an increase in risk of mortality from COVID-19 pneumonia. In a sex-, age- and comorbid illness-matched case-control study, CD3+CD8+ T-cells ≤75 cells·μL-1 and cardiac troponin I ≥0.05 ng·mL-1 remained as predictors for high mortality from COVID-19 pneumonia.We identified four risk factors: age ≥65 years, pre-existing concurrent cardiovascular or cerebrovascular diseases, CD3+CD8+ T-cells ≤75 cells·μL-1 and cardiac troponin I ≥0.05 ng·mL-1 The latter two factors, especially, were predictors for mortality of COVID-19 pneumonia patients.

Conflict of interest statement

Conflict of interest: Rong-Hui Du has nothing to disclose. Conflict of interest: Li-Rong Liang has nothing to disclose. Conflict of interest: Cheng-Qing Yang has nothing to disclose. Conflict of interest: Wen Wang has nothing to disclose. Conflict of interest: Tan-Ze Cao has nothing to disclose. Conflict of interest: Ming Li has nothing to disclose. Conflict of interest: Guang-Yun Guo has nothing to disclose. Conflict of interest: Juan Du has nothing to disclose. Conflict of interest: Chun-Lan Zheng has nothing to disclose. Conflict of interest: Qi Zhu has nothing to disclose. Conflict of interest: Ming Hu has nothing to disclose. Conflict of interest: Xu-Yan Li has nothing to disclose. Conflict of interest: Peng Peng has nothing to disclose. Conflict of interest: Huan-Zhong Shi has nothing to disclose.

Copyright ©ERS 2020.

References

    1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733. doi:10.1056/NEJMoa2001017
    1. Li Q, Guan X, Wu P, et al. . Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199–1207. doi:10.1056/NEJMoa2001316
    1. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020; 395: 689–697. doi:10.1016/S0140-6736(20)30260-9
    1. National Health Commission of the People's Republic of China. More than 20,000 medical staff were sent to Hubei Province. Date last accessed: 2 March 2020.
    1. Johns Hopkins University Center for Systems Science and Engineering. Wuhan coronavirus (2019-nCoV) global cases. Date last accessed: 22 March 2020.
    1. Paules CI, Marston HD, Fauci AS. Coronavirus infections – more than just the common cold. JAMA 2020; in press [10.1001/jama.2020.0757].
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; in press [10.1001/jama.2020.2648].
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5
    1. Chen N, Zhou M, Dong X, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513. doi:10.1016/S0140-6736(20)30211-7
    1. Wang D, Hu B, Hu C, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; in press [10.1001/jama.2020.1585].
    1. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Date last updated: 28 January 2020. Date last accessed: 2 March 2020.
    1. Guan WJ, Ni ZY, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; in press [10.1056/NEJMoa2002032].
    1. Perlman S. Another decade, another coronavirus. N Engl J Med 2020; 382: 760–762. doi:10.1056/NEJMe2001126
    1. Zhong NS, Zheng BJ, Li YM, et al. . Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362: 1353–1358. doi:10.1016/S0140-6736(03)14630-2
    1. Christian MD, Poutanen SM, Loutfy MR, et al. . Severe acute respiratory syndrome. Clin Infect Dis 2004; 38: 1420–1427. doi:10.1086/420743
    1. Arabi YM, Balkhy HH, Hayden FG, et al. . Middle East respiratory syndrome. N Engl J Med 2017; 376: 584–594. doi:10.1056/NEJMsr1408795
    1. National Health Commission of the People's Republic of China. Latest on the novel coronavirus outbreak. Date last accessed: 24 March 2020.
    1. Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med 2014; 20: 233–241. doi:10.1097/MCP.0000000000000046
    1. Chen H, Hou J, Jiang X, et al. . Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 2005; 175: 591–598. doi:10.4049/jimmunol.175.1.591
    1. Hong KH, Choi JP, Hong SH, et al. . Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 2018; 73: 286–289. doi:10.1136/thoraxjnl-2016-209313
    1. Liu Y, Yang Y, Zhang C, et al. . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63: 364–374. doi:10.1007/s11427-020-1643-8
    1. National Health Commission of the People's Republic of China. Press conference of the State Council of the People's Republic of China. . Date last accessed: 2 March 2020.

Source: PubMed

3
Abonner